Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antidepressant Labeling Should Reflect Negative Pediatric Studies

Executive Summary

Antidepressant labeling should be revised to reflect negative efficacy data for pediatric patients, a joint FDA advisory committee suggested Feb. 2

You may also be interested in...



HMO Claims Study Will Provide Next Data For Antidepressant Safety Review

A 24,000-patient pediatric safety study currently under peer review could provide the next pool of data on the relationship between antidepressants and suicidality

HMO Claims Study Will Provide Next Data For Antidepressant Safety Review

A 24,000-patient pediatric safety study currently under peer review could provide the next pool of data on the relationship between antidepressants and suicidality

Antidepressant Suicidality Needs Interim Risk Management, FDAer Maintains

FDA should establish an interim risk management plan to discourage pediatric antidepressant use, FDA epidemiologist Andrew Mosholder, MD, maintained in an Aug. 16 memo

Related Content

UsernamePublicRestriction

Register

PS043282

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel